Reporter ribozymes that allow monitoring of protein–nucleic acid and protein–protein interactions facilitate rapid identification of inhibitors for use in drug discovery.
This is a preview of subscription content, log in via an institution to check access.
© Bob Crimi
References
Ellington, A.D. & Szostak, J.W. Nature 346, 818–822 (1990).
Tuerk, C. & Gold, L. Science 249, 505–510 (1990).
Eaton, B.E., Gold, L. & Zichi, D.A. Chem. Biol. 2, 633–638 (1995).
Ellington, A.D. & Conrad, R. Biotechnol. Annu. Rev. 1, 185–214 (1995)
Hartig J.S. et al. Nat. Biotechnol. 20, 717–722 (2002).
Seetharaman, S., Zivarts, M., Sudarsan, N. & Breaker, R.R. Nat. Biotechnol. 19, 336–341 (2001).
Robertson, M.P. & Ellington, A.D. Nucleic Acids Res. 28, 1751–1759 (2000).
Hesselberth, J., Robertson, M.P., Jhaveri, S. & Ellington, A.D. J. Biotechnol. 74, 15–25 (2000).
Green, L.S., Bell, C. & Janjic, N. Aptamers as reagents for high throughput screening. BioTechniques 30, 1094–1110 (2001).
Fredriksson, S. et al. Nat. Biotechnol. 20, 473–477 (2002).
Petach, H. & Gold, L. Curr. Opin. Biotechnol., in press (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gold, L. RNA as the catalyst for drug screening. Nat Biotechnol 20, 671–672 (2002). https://doi.org/10.1038/nbt0702-671
Issue Date:
DOI: https://doi.org/10.1038/nbt0702-671
- Springer Nature America, Inc.